Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

Goal

Statin Intolerance

Serial IVUS

Effect on CHD Events of Lowering LDL-C

Percent Change in LDL-C During Treatment

Primary Endpoint: PAV

Percent of Patients Showing Regression in PAV

Exploratory Subgroup Baseline LDL-C Less Than 70 mg/dL

Safety

Statin Intolerance

Risk Factors and Workup

Common Drugs

Autoimmune Myopathy

Initial Management of Statin Intolerance

GAUSS-3 Trial

Who Gets the PCSK9 Inhibitor?

Patients With FH and Access to Care

FH Prevalence

FH Is Severely Underdiagnosed

The FH Foundation

Access to PCSK9 Inhibitors

Identification and Diagnosis

Treatment in Children and Young Adults

Guidance for the Use of PCSK9 Inhibitors

Progression and Regression of CAD

Atherosclerosis -- A Disease Process

Percent Change in LDL-C During Treatment

Lower Is Better

Abbreviations